Liquid Chromatography–Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine Therapy
- 1 November 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (11), 2074-2084
- https://doi.org/10.1373/clinchem.2005.050831
Abstract
Background: Polymorphic thiopurine S-methyltransferase (TPMT) is a major determinant of thiopurine toxicity. Methods: We extracted 6-thioguanine nucleotides (6-TGNs) and 6-methylmercaptopurine nucleotides (6-MMPNs) from erythrocytes with perchloric acid and converted them to 6-thioguanine (6-TG) and a 6-methylmercaptopurine (6-MMP) derivative during a 60-min acid hydrolysis step. The liquid chromatography system consisted of a C18 column with an ammonium acetate–formic acid–acetonitrile buffer. 8-Bromoadenine was the internal standard. Analytes were measured with positive ionization and multiple reaction monitoring mode. With PCR–restriction fragment length polymorphism analysis and TaqMan allelic discrimination, common TPMT alleles (*1, *2, *3A, *3B, *3C) were determined in 31 792 individuals. We used perchloric acid extraction, acid hydrolysis, and HPLC with ultraviolet detection to measure erythrocyte 6-TG and 6-MMP nucleotide concentrations in 6189 patients with inflammatory bowel disease receiving azathioprine/6-mercaptopurine therapy. Results: Intra- and interday imprecision were 450 pmol/8 × 108 erythrocytes (concentration associated with increased risk for leukopenia), but an 8.2-fold lower risk for 6-MMPNs >5700 pmol/8 × 108 erythrocytes (concentration associated with increased risk for hepatotoxicity). Conclusions: The liquid chromatography–tandem mass spectrometry method can be applied to the routine monitoring of thiopurine therapy. The association between TPMT genotype and metabolite concentrations illustrates the utility of pharmacogenetics in the management of patients undergoing treatment with thiopurines.Keywords
This publication has 33 references indexed in Scilit:
- Rapid, Long-Range Molecular Haplotyping of Thiopurine S-Methyltransferase (TPMT*) *3A, *3B, and *3CClinical Chemistry, 2004
- Phenotyping and genotyping study of thiopurine S‐methyltransferase in healthy Chinese children: A comparison of Han and Yao ethnic groupsBritish Journal of Clinical Pharmacology, 2004
- Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in KoreaRheumatology, 2003
- AZATHIOPRINE-INDUCED FATAL MYELOSUPPRESSION IN A RENAL-TRANSPLANT RECIPIENT WHO CARRIED HETEROZYGOUS TPMT*1/*3CTransplantation, 2003
- Ethnic differences in thiopurine methyltransferase pharmacogeneticsPharmacogenetics and Genomics, 1999
- Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cellsPharmacogenetics, 1999
- The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populationsPharmacogenetics, 1999
- Azathioprine‐induced severe pancytopenia due to a homozygous two‐point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA‐B27‐associated spondylarthritisArthritis & Rheumatism, 1997
- Should 6- Thioguanine Nucleotides Be Monitored in Heart Transplant Recipients Given Azathioprine?Therapeutic Drug Monitoring, 1996
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993